News | May 29, 2007

Sickest Heart Patients May Not Get Treatments They Need

May 30, 2007 -- The Canadian Press reports this week that people in the greatest need of cardiac medications and interventions are less likely than moderately ill patients to get the full range of heart drugs and procedures, and it may be because they fail the "eyeball" test.

Two American cardiologists have suggested that doctors may view these patients, the sickest of the sick, as too ill to benefit from invasive treatments like catheterization or too depressed or unwell to deal with the hassle of more medication in what is likely already a multi-pill daily regime.

Dr. John Spertus of the University of Missouri, Kansas City and Dr. Mark Furman of the University of Massachusetts Medical School express their views in an editorial in the "Archives of Internal Medicine."

Their editorial accompanies two studies by Canadian research teams that found that sicker patients were less likely to be getting an important cholesterol lowering drug called a statin or to undergo cardiac catheterization.

The studies add support to what's called the treatment-risk paradox, a phenomenon first described by researchers at Toronto's Institute for Clinical Evaluative Studies.

They reported in 2004 that patients who would benefit most from cardiac interventions were least likely to be getting them.


Related Content

News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
News | Cardiovascular Clinical Studies

Jan. 13, — A new cohort study among 103,642 adults found that current use of cigars was associated with increased risk ...

Home January 14, 2025
Home
News | Cardiovascular Clinical Studies

Nov. 22, 2024 — BridgeBio Pharma, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved ...

Home November 25, 2024
Home
Subscribe Now